Pancreatic is the most common cancer with the gene mutation. In our initial Phase1b study, stable disease was achieved in the patients with solid tumours (pancreatic and colorectal) early in the trials. Whislt no significant efficacy was achieved, it was stated that the data derived was encouraging. They were on the lowest dose.
I thought it was interesting too that SYC made reference to lung cancer in context to considering any combination trials with PTX100. I think that it was why there is so much excitement behind our TCL trial. If we can get an accelerated approval as a monotherapy, then doors will open for PTX100 as a RAS pathway inhibitor.
It was stated in the panel interview Dan Shelly attended, that the FDA are focusing on targeted therapies and universal platforms (the two areas which PTX happen to be primarily involved in). I saved a couple of articles since first investing in PTX on RAS. I'll do a quick search.
PTX Price at posting:
8.9¢ Sentiment: Buy Disclosure: Held
